Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual, invasive,early breast cancer after neoadjuvant therapy: a randomized phase 3 trial (DESTINY-Breast05). SABCS 2021, Poster - Geyer, C; Untch, M; Prat, A
et al.